318 related articles for article (PubMed ID: 24630239)
1. Effects of the immunosuppressant rapamycin on the expression of human α2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts.
Tamaki Z; Asano Y; Kubo M; Ihn H; Tada Y; Sugaya M; Kadono T; Sato S
J Dermatol Sci; 2014 Jun; 74(3):251-9. PubMed ID: 24630239
[TBL] [Abstract][Full Text] [Related]
2. Akt blockade downregulates collagen and upregulates MMP1 in human dermal fibroblasts.
Bujor AM; Pannu J; Bu S; Smith EA; Muise-Helmericks RC; Trojanowska M
J Invest Dermatol; 2008 Aug; 128(8):1906-14. PubMed ID: 18323784
[TBL] [Abstract][Full Text] [Related]
3. 2-Methoxyestradiol inhibits bleomycin-induced systemic sclerosis through suppression of fibroblast activation.
Zhu L; Song Y; Li M
J Dermatol Sci; 2015 Jan; 77(1):63-70. PubMed ID: 25465161
[TBL] [Abstract][Full Text] [Related]
4. Effect of granulocyte macrophage-colony stimulating factor on extracellular matrix deposition by dermal fibroblasts from patients with scleroderma.
Postiglione L; Ladogana P; Montagnani S; di Spigna G; Castaldo C; Turano M; Bruno EM; Di Meglio F; Riccio A; Rossi G
J Rheumatol; 2005 Apr; 32(4):656-64. PubMed ID: 15801021
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of the immunosuppressant FK-506 on human alpha2(I) collagen gene expression and transforming growth factor beta signaling in normal and scleroderma fibroblasts.
Asano Y; Ihn H; Yamane K; Jinnin M; Mimura Y; Tamaki K
Arthritis Rheum; 2005 Apr; 52(4):1237-47. PubMed ID: 15818662
[TBL] [Abstract][Full Text] [Related]
6. Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1.
Bujor AM; Haines P; Padilla C; Christmann RB; Junie M; Sampaio-Barros PD; Lafyatis R; Trojanowska M
Int J Mol Med; 2012 Dec; 30(6):1473-80. PubMed ID: 23041765
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan and its metabolite SN38 inhibits procollagen I production of dermal fibroblasts from Systemic Sclerosis patients.
Lapoirie J; Tran L; Piazza L; Contin-Bordes C; Truchetet ME; Bonnet F
Sci Rep; 2021 Sep; 11(1):18011. PubMed ID: 34504265
[TBL] [Abstract][Full Text] [Related]
8. CXCL17-mediated downregulation of type I collagen via MMP1 and miR-29 in skin fibroblasts possibly contributes to the fibrosis in systemic sclerosis.
Shimada S; Makino K; Jinnin M; Sawamura S; Kawano Y; Ide M; Kajihara I; Makino T; Fukushima S; Ihn H
J Dermatol Sci; 2020 Dec; 100(3):183-191. PubMed ID: 33055012
[TBL] [Abstract][Full Text] [Related]
9. Minocycline does not alter collagen type I metabolism of dermal fibroblasts in culture.
Anderegg U; Prieb J; Hildebrandt G; Saalbach A
Arch Dermatol Res; 2002 May; 294(3):103-8. PubMed ID: 12029495
[TBL] [Abstract][Full Text] [Related]
10. Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts.
Brembilla NC; Montanari E; Truchetet ME; Raschi E; Meroni P; Chizzolini C
Arthritis Res Ther; 2013 Oct; 15(5):R151. PubMed ID: 24289089
[TBL] [Abstract][Full Text] [Related]
11. Increased accumulation of extracellular thrombospondin-2 due to low degradation activity stimulates type I collagen expression in scleroderma fibroblasts.
Kajihara I; Jinnin M; Yamane K; Makino T; Honda N; Igata T; Masuguchi S; Fukushima S; Okamoto Y; Hasegawa M; Fujimoto M; Ihn H
Am J Pathol; 2012 Feb; 180(2):703-14. PubMed ID: 22142808
[TBL] [Abstract][Full Text] [Related]
12. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.
Akamata K; Asano Y; Aozasa N; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sato S
Arthritis Res Ther; 2014 Apr; 16(2):R86. PubMed ID: 24708674
[TBL] [Abstract][Full Text] [Related]
13. Basic fibroblast growth factor inhibits basal and transforming growth factor-beta induced collagen alpha 2(I) gene expression in scleroderma and normal fibroblasts.
Ichiki Y; Smith EA; LeRoy EC; Trojanowska M
J Rheumatol; 1997 Jan; 24(1):90-5. PubMed ID: 9002017
[TBL] [Abstract][Full Text] [Related]
14. Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts.
Fineschi S; Reith W; Guerne PA; Dayer JM; Chizzolini C
FASEB J; 2006 Mar; 20(3):562-4. PubMed ID: 16410344
[TBL] [Abstract][Full Text] [Related]
15. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
[TBL] [Abstract][Full Text] [Related]
16. Effects of hepatocyte growth factor on the expression of type I collagen and matrix metalloproteinase-1 in normal and scleroderma dermal fibroblasts.
Jinnin M; Ihn H; Mimura Y; Asano Y; Yamane K; Tamaki K
J Invest Dermatol; 2005 Feb; 124(2):324-30. PubMed ID: 15675950
[TBL] [Abstract][Full Text] [Related]
17. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha.
Chizzolini C; Parel Y; De Luca C; Tyndall A; Akesson A; Scheja A; Dayer JM
Arthritis Rheum; 2003 Sep; 48(9):2593-604. PubMed ID: 13130479
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts.
Goffin L; Seguin-Estévez Q; Alvarez M; Reith W; Chizzolini C
Arthritis Res Ther; 2010; 12(2):R73. PubMed ID: 20429888
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.
Kawaguchi Y; Takagi K; Hara M; Fukasawa C; Sugiura T; Nishimagi E; Harigai M; Kamatani N
Arthritis Rheum; 2004 Jan; 50(1):216-26. PubMed ID: 14730619
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
